Anthem Biosciences

Anthem Biosciences, a prominent contract research and manufacturing services (CRAMS) company, has unveiled its initial public offering (IPO) price band between Rs. 530 and Rs. 570 per share. This public issue, poised to raise substantial capital, underlines the growing appetite for biotech and pharmaceutical investments in India. Market observers anticipate strong participation given Anthem’s diversified service offerings, robust global clientele, and consistent financial growth.

Anthem Biosciences, a leading contract development and manufacturing organization (CDMO) specializing in pharmaceuticals and biotechnology, is gearing up for its highly anticipated initial public offering on July 14. The IPO, expected to raise Rs. 3,395 crore, underscores the company’s ambitions to fuel its next phase of growth by enhancing manufacturing capacities and bolstering research and development.

In a significant move for the Indian stock market, Anthem Biosciences, Aye Finance, BlueStone Jewellery and Lifestyle, and GK Energy have received the go-ahead from the Securities and Exchange Board of India (Sebi) to launch their respective Initial Public Offerings (IPOs). Collectively, these companies are looking to raise a substantial Rs. 6,345 crore through their public offerings. This approval paves the way for these companies to tap into the equity markets, presenting new opportunities for investors and marking a critical milestone for the Indian IPO landscape.